Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Crispr Therapeutics AG (CRSP) vs Dollar Tree, Inc. (DLTR) Price & Performance

Crispr Therapeutics AGTrade
Dollar Tree, Inc.Trade

Price performance (Past 24H)

Key statistics

Crispr Therapeutics AG vs Dollar Tree, Inc. — how do they compare? Crispr Therapeutics AG trades at $50.55 (market cap $4.97B), while Dollar Tree, Inc. trades at $126.43 (market cap $23.94B). The key difference: Dollar Tree, Inc. is far larger — about 4.8× Crispr Therapeutics AG's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.

CRSPDLTR
Market Cap
$4.97B$23.94B
Sector
HealthHealth
52-Week High
$76.78$141.21
52-Week Low
$44.34$85.04
Enterprise Value
$3.32B$30.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Crispr Therapeutics AG

CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.

The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.

Dollar Tree, Inc.

Dollar Tree (DLTR) trades at $126.38, up 1.18% today, with a bullish technical signal and strong recent earnings beats. The company's fundamentals show a net loss in 2025 but improving cash flow and a $2.5 billion share repurchase authorization signal confidence. Analyst consensus is a Buy with a $131 price target, though valuation ratios like P/E of 20.29 and P/B of 6.93 reflect moderate pricing.

The outlook is positive due to earnings momentum and cost controls, but risks include traffic softness and tariff pressures. Upside potential exists if margin gains and multi-price strategy sustain growth, yet investors must weigh high debt and competitive headwinds against cash flow strength and institutional support.

Returns comparison

Trailing returns across standard periods

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP

About Dollar Tree, Inc.

Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.

Read more on DLTR